Docket No. 381092000624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Examiner: B. J. Packard

Terrance P. SNUTCH et al.

Application No.: 10/821,389

Filing Date: April 9, 2004

For: CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED

FROM PIPERAZINE

Group Art Unit: 1612

Confirmation No.: 1599

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the non-patent literature are submitted herewith. The Examiner is requested to make these documents of record

I hereby certify that no item of information was first cited in any communication from a foreign patent office in a counterpart foreign application or, to the best of my knowledge after making a reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.)

	This In	formation Disclosure Statement is submitted:	
	With	the application; accordingly, no fee or separate requirements are required.	
	Befor	re the mailing of a first Office Action after the filing of a Request for Continued	
	Exam	nination under 37 C.F.R. § 1.114. However, if applicable, a certification under 37	
	C.F.F	R. § 1.97 (e)(1) has been provided.	
	With	Within three months of the application filing date or before mailing of a first Office Action	
	on the	e merits; accordingly, no fee or separate requirements are required. However, if	
	applie	cable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.	
	After	After receipt of a first Office Action on the merits but before mailing of a final Office Action	
	or Notice of Allowance.		
		A fee is required. Accordingly, a Fee Transmittal Form (PTO/SB/17) is attached to	
		this submission.	
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is	
		believed to be due.	
\boxtimes	After mailing of a final Office Action or Notice of Allowance, but before payment of the		
	Issue Fee.		
	\boxtimes	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee is provided via	
		FES-Web	

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to <u>Deposit Account No. 03-1952</u> referencing 381092000624.

Dated: October 12, 2009 Respectfully submitted,

By: /Kate H. Murashige/
Kate H. Murashige
Registration No.: 29,959
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5112